Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06238635 · ClinicalTrials.gov registry record · Phase 2

Dostarlimab and Cobolimab in Advanced Cervical Cancer

A Phase 2 study of Cervical Cancer and Recurrent Cervical Carcinoma, sponsored by Meghan Shea.

Active
Registry status
Phase 2
Development phase
66
Enrollment target
2
Study locations

NCT06238635 is a Phase 2 study of Cervical Cancer and Recurrent Cervical Carcinoma that is active but no longer recruiting, run by Meghan Shea. The registered enrollment target is 66 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06238635, a Phase 2 study of Cervical Cancer and Recurrent Cervical Carcinoma, is active but no longer recruiting, sponsored by Meghan Shea.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
66 participants
Enrollment target
2
Study locations

Study Summary

This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

Conditions Studied

Cervical Cancer Recurrent Cervical Carcinoma Metastatic Cervical Cancer Metastatic Cervical Carcinoma Advanced Cervical Carcinoma

Interventions

  • DRUG Dostarlimab
  • DRUG Cobolimab

Study Locations (2)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2024-03-11
Est. Completion 2027-07-15
Phase Phase 2

Sponsor

Meghan Shea

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06238635

The ClinicalTrials.gov registry entry for NCT06238635 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Meghan Shea, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Dostarlimab is the first listed.

NCT06238635 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06238635 about?

NCT06238635 is a clinical study titled "Dostarlimab and Cobolimab in Advanced Cervical Cancer". This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

What is the current status of trial NCT06238635?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-03-11. Estimated completion is 2027-07-15.

What conditions does trial NCT06238635 study?

This clinical trial studies the following conditions: Cervical Cancer, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Advanced Cervical Carcinoma.

What interventions are being tested in trial NCT06238635?

The interventions under investigation include: Dostarlimab (DRUG), Cobolimab (DRUG).

Who is sponsoring clinical trial NCT06238635?

This trial is sponsored by Meghan Shea, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06238635 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cervical Cancer

All registered trials for this condition

Recurrent Cervical Carcinoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.